# Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients

> **NCT04263597** · PHASE1,PHASE2 · COMPLETED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 70 (actual)

## Conditions studied

- Hematopoietic Stem Cell Transplant

## Interventions

- **DRUG:** 2'-fucosyllactose

## Key facts

- **NCT ID:** NCT04263597
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-26
- **Primary completion:** 2025-05-23
- **Final completion:** 2025-05-23
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04263597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04263597, "Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04263597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*